Related Experiment Videos
Pegaptanib for wet macular degeneration.
1National Registry of Drug-Induced Ocular Side Effects, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon 97239-4197, USA. fraunfer@ohsu.edu
Drugs of Today (Barcelona, Spain : 1998)
|January 6, 2006
Summary
Pegaptanib sodium injection is a novel aptamer treatment for wet age-related macular degeneration (AMD) by inhibiting vascular endothelial growth factor (VEGF). This therapy offers a viable option for managing angiogenesis in AMD, despite potential adverse events.
Area of Science:
- Ophthalmology
- Molecular Biology
- Pharmacology
Background:
- Wet age-related macular degeneration (AMD) involves pathological angiogenesis in the macula.
- Neovascular AMD is a leading cause of severe vision loss in individuals over 60.
- Vascular Endothelial Growth Factor (VEGF) is implicated in the angiogenesis of wet AMD.
Purpose of the Study:
- To introduce pegaptanib sodium injection as a new therapeutic agent for wet AMD.
- To explain the mechanism of action of pegaptanib as a selective VEGF antagonist.
- To discuss the potential of aptamer-based therapies in managing macular degeneration.
Main Methods:
- Pegaptanib, an aptamer, is administered via intravitreal injection.
- Pegaptanib selectively binds to the VEGF165 isoform.
- This binding inhibits VEGF from interacting with its receptor, blocking angiogenesis and vascular permeability.
Main Results:
- Pegaptanib functions as a selective VEGF antagonist.
- The aptamer prevents VEGF-mediated angiogenesis and vascular permeability.
- Current treatments for AMD, including surgery, often result in vision loss.
Conclusions:
- Pegaptanib sodium injection represents a viable treatment option for wet AMD.
- Aptamer-based therapies offer a promising approach to managing angiogenesis in macular degeneration.
- Ongoing research in macular degeneration is advancing treatment possibilities.